Financial Counselors Inc. bought a new position in Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 7,538 shares of the medical equipment provider’s stock, valued at approximately $209,000.

Several other hedge funds and other institutional investors also recently modified their holdings of BSX. UBS Asset Management Americas Inc. grew its holdings in shares of Boston Scientific Corporation by 9.1% in the 1st quarter. UBS Asset Management Americas Inc. now owns 3,435,806 shares of the medical equipment provider’s stock worth $85,448,000 after acquiring an additional 286,705 shares during the last quarter. Commerce Bank acquired a new position in shares of Boston Scientific Corporation in the 1st quarter worth $207,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in shares of Boston Scientific Corporation by 29.6% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 101,142 shares of the medical equipment provider’s stock worth $2,515,000 after acquiring an additional 23,084 shares during the last quarter. Boston Family Office LLC grew its holdings in shares of Boston Scientific Corporation by 4.6% in the 1st quarter. Boston Family Office LLC now owns 43,550 shares of the medical equipment provider’s stock worth $1,083,000 after acquiring an additional 1,925 shares during the last quarter. Finally, Toronto Dominion Bank grew its holdings in shares of Boston Scientific Corporation by 56.7% in the 1st quarter. Toronto Dominion Bank now owns 367,924 shares of the medical equipment provider’s stock worth $9,150,000 after acquiring an additional 133,121 shares during the last quarter. Institutional investors and hedge funds own 90.52% of the company’s stock.

Shares of Boston Scientific Corporation (NYSE:BSX) opened at 28.93 on Friday. The firm has a market cap of $39.70 billion, a PE ratio of 51.75 and a beta of 1.09. Boston Scientific Corporation has a 52-week low of $19.67 and a 52-week high of $29.40. The company’s 50-day moving average price is $27.28 and its 200-day moving average price is $26.52.

Boston Scientific Corporation (NYSE:BSX) last released its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.01. The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The company’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.27 EPS. Equities analysts expect that Boston Scientific Corporation will post $1.26 earnings per share for the current fiscal year.

A number of brokerages recently issued reports on BSX. Zacks Investment Research cut Boston Scientific Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. UBS AG reaffirmed a “buy” rating and issued a $31.00 target price (up previously from $30.00) on shares of Boston Scientific Corporation in a research report on Tuesday, August 1st. BidaskClub cut Boston Scientific Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Boston Scientific Corporation in a research report on Wednesday, June 28th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $30.00 target price on shares of Boston Scientific Corporation in a research report on Wednesday, June 21st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $29.88.

In other Boston Scientific Corporation news, EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction dated Thursday, June 29th. The stock was sold at an average price of $28.02, for a total transaction of $434,310.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy A. Pratt sold 10,104 shares of the stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $27.46, for a total value of $277,455.84. Following the transaction, the executive vice president now owns 185,742 shares of the company’s stock, valued at approximately $5,100,475.32. The disclosure for this sale can be found here. In the last quarter, insiders have sold 275,257 shares of company stock valued at $7,512,394. Corporate insiders own 0.74% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/09/16/financial-counselors-inc-takes-position-in-boston-scientific-corporation-bsx.html.

Boston Scientific Corporation Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.